Association of ADIPOQ gene polymorphisms and coronary artery disease risk: a meta-analysis based on 12 465 subjects

Related Experiment Video

Updated: May 24, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Yuan Yang1, Fan Zhang, Rongjing Ding

  • 1Department of Cardiology, First Affiliated Hospital, Chongqing Medical University, Chongqing, 400016, China.

Thrombosis Research
|March 6, 2012
PubMed

Insights

Genetic variations in the ADIPOQ gene are linked to coronary artery disease (CAD) risk. Specific polymorphisms, like rs266729 and rs822395, increase CAD risk, while rs1501299 decreases it, particularly in certain ethnicities.

Area of Science:

  • Genetics and Cardiovascular Disease
  • Molecular Epidemiology

Background:

  • Coronary artery disease (CAD) is a leading global cause of mortality.
  • The role of the ADIPOQ gene in CAD risk has been investigated, but findings are inconsistent.

Purpose of the Study:

  • To evaluate the association between ADIPOQ gene polymorphisms and CAD risk.
  • To synthesize evidence from multiple case-control studies.

Main Methods:

  • Systematic literature search of PubMed and EMBASE up to October 2011.
  • Inclusion of 17 case-control studies involving 12,465 subjects.
  • Analysis of four single nucleotide polymorphisms (SNPs) in the ADIPOQ gene using odds ratios (ORs).

Main Results:

  • No association between rs2241766 and CAD risk.
  • Increased CAD risk associated with rs266729 (allele contrast, dominant model) and rs822395 (additive, recessive models).
  • Decreased CAD risk associated with rs1501299 (additive, recessive models), with ethnicity-specific effects observed (rs266729 in Asians, rs1501299 in Caucasians).

Conclusions:

  • ADIPOQ gene polymorphisms are associated with CAD risk.
  • Different SNPs exhibit varying effects on CAD risk, with ethnicity-dependent associations.
  • The overall strength of these genetic associations with CAD risk is mild to moderate.
Abstract

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...